Log in to MyKarger to check if you already have access to this content.
Buy
FullText & PDF
Unlimited re-access via MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Select
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Learn more
Rent via DeepDyve
Unlimited fulltext viewing of this article
Organize, annotate and mark up articles
Printing and downloading restrictions apply
Start free trial
Subscribe
Access to all articles of the subscribed year(s) guaranteed for 5 years
Unlimited re-access via Subscriber Login or MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
Subcription rates
Select
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
Abstract
Introduction
Previous preclinical studies reported that the level of serum EphrinA1 was associated with blood-brain barrier (BBB) disruption, while its role in predicting parenchymal hematoma (PH) after ischemic stroke has not been investigated. We aimed to explore the association between the level of serum EphrinA1 and PH in patients with ischemic stroke.
Methods
Patients with ischemic stroke within 24 hours after onset from West China hospital, Sichuan University, were prospectively enrolled between January 2017 and December 2019.The level of serum EphrinA1 at baseline was measured within 24 hours after admission. PH was diagnosed as hematoma within the infarct territory detected on the brain CT/MRI scans within 7 days after onset, but not on the initial scan according to European Cooperative Acute Stroke Study (ECASS) III criteria. The association between the level of serum EphrinA1 and PH after ischemic stroke was assessed by multiple logistic regression analysis.
Results
A total of 667 patients were included in final analysis. The mean age was 67.20 ± 14.31 years and 57.87% (368/667) were men. Of the 667 patients, 65(9.75%) patients had PH. The median of EphrinA1 on admission was 82.83 ng/mL (IQR, 70.11–93.75 pg/mL). Compared with patients without PH, those with PH had higher level of serum EphrinA1 (P=0.024). Then patients were divided into 3 categories based on EphrinA1 tertiles (T1, 93.75 pg/mL, n=22). After adjusting for age, sex, atrial fibrillation, smoking, statins, anti-platelets, Trail of Org 10172 in Acute Stroke Treatment (TOAST) classification and National Institutes of Health Stroke Scale (NIHSS) score≥15, patients in the second and third EphrinA1 tertiles showed a significant increase in PH compared with those in the lowest tertile (OR2.44, 95% CI1.10-5.40, P=0.028; OR 2.61, 95% CI 1.19-5.74, P=0.017, respectively). Additional adjusting for reperfusion therapy（thrombolysis and/or endovascular therapy）, only patients in the highest group(tertile 3) had a significantly higher risk of PH compared to the lowest group (OR 2.30, 95% CI1.03-5.13, P=0.042).
Conclusion
Higher serum EphrinA1 is independently associated with higher risk of PH after ischemic stroke. Future studies with larger sample size are needed to validate our findings and elucidate the potential role of EphrinA1 in PH.
S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Comments (0)